5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Type of Product (Instruments, Consumables, Software, Others), Application, End User, and Geography.
Fastest Growing Market:
Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. This method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost. The need for cost containment in pharmaceutical R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine, present significant growth opportunities in the market.
High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances, such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
|Primary and Secondary Screening|
|Target Identification and Validation|
|Pharmaceutical and Biotechnology Companies|
|Academic and Government Institutions|
|Contract Research Organisation|
Report scope can be customized per your requirements. Click here.
Based on the product segment, the high content screening market is further segmented into instruments, consumables, software, others. Among all high content screening products, the instrument segment occupies the largest share of the market. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.
To understand key trends, Download Sample Report
The high content screening market in APAC is expected to increase at the highest CAGR during the forecast period. Factors, such as increasing drug discovery research, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure are driving the growth of the HCS market in this region.
To understand geography trends, Download Sample Report.
For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. The majority of large global players are based out of the United States and these players have expertise in other biotechnology/medical-technology verticals as well, which helps them in controlling the major market share, through a presence in the allied markets.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Funding and Venture Capital Investments Across Developed Markets
4.2.2 Increasing Applications of HCS in Life Science Research
4.2.3 Advancements in Informatic Solutions and Imaging Systems
4.3 Market Restraints
4.3.1 Lower Adoption of HCS Instruments Due to Their High Prices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
184.108.40.206 Cell Imaging and Analysis Systems
220.127.116.11 Flow Cytometers
18.104.22.168 Reagents and Assay Kits
22.214.171.124 Other Consumables
5.2.1 Primary and Secondary Screening
5.2.2 Target Identification and Validation
5.2.3 Toxicity Studies
5.2.4 Compound Profiling
5.2.5 Other Applications
5.3 End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic and Government Institutions
5.3.3 Contract Research Organisation
5.4.1 North America
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Danaher Corporation
6.1.3 Perkinelmer Inc.
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 Biotek Instruments Inc.
6.1.7 Bio-Rad Laboratories Inc.
6.1.8 Yokogawa Electric Corporation
6.1.9 Merck KGaA
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments